Mounjaro Price Increase News: What Changed and What It Means for You

One transparent price covers your free consultation, clinical review by a GPhC-registered Independent Prescriber, your prescription, and the medicine itself.
Free next-working-day tracked delivery by DPD, dispatched the same day as approval for orders placed before 12pm Monday to Friday.
No subscription, no auto-renewal — every repeat order is reviewed by a clinician before it ships.
Priority aftercare seven days a week, included as standard, no hidden support fees.

Eli Lilly raised Mounjaro's UK list price on 1 September 2025. That single change rippled through every private weight-loss clinic and online pharmacy in the country, pushing the highest-dose pen from around £122 to around £330 per four-week supply. It was widely reported in August 2025, and the questions we've been fielding ever since are practical ones: what exactly changed, does it affect every dose, and how do private providers pass that cost on? Mounjaro is a prescription-only medicine, so the price you pay always sits inside a clinical package, not a retail transaction — and understanding the difference matters when you're comparing numbers online.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The price increase, what it included, and how to read the numbers now

What Eli Lilly actually changed on 1 September 2025

The published UK list price for Mounjaro's highest dose rose sharply from around £122 to approximately £330 per pen, a roughly 170% increase on the list price alone. Lower doses saw smaller but still meaningful rises. These figures come from Lilly's own UK list-price communications, widely reported in the trade press during August 2025, ahead of the change taking effect. If you want to follow how those figures have shifted over time, our Mounjaro price news page tracks the latest updates as they are published.

List price is not the same as what patients pay at a private pharmacy. Providers negotiate their own supply terms and set their own margins. What you'll find across the market is a broad range: typically somewhere between £149 and £375 per month depending on the dose and the clinic. How private Mounjaro pricing is structured is worth reading before comparing quotes, because the dose matters enormously, a 2.5mg starter pen and a 15mg maintenance pen are not comparable products, and some advertised prices lead with the entry dose.

The price adjustment did not affect Mounjaro's clinical profile or its NICE recommendation. NICE published its appraisal of tirzepatide (TA1026) in December 2024 and it stands regardless of list-price movements. The medicine remained the same; the commercial terms changed.

Which doses were hit hardest by the increase

The September 2025 increase was not uniform across the range. The highest maintenance doses (10mg, 12.5mg and 15mg) absorbed the largest absolute rises. Patients who had locked in treatment at lower starter doses found the picture different when they began titrating upward.

If you're reading this because your current dose price jumped mid-treatment, that's a real and frustrating experience. Timing matters here: patients who started before September 2025 and were mid-titration when the price changed faced the increase at a point they hadn't budgeted for. There's more detail on the dose-specific picture in our coverage of the 5mg price change and the starter 2.5mg pen changes.

It's also worth knowing that not every provider increased their patient-facing prices by the full list-price delta. Some absorbed part of the rise; others passed it through in full. None of that changes what you owe clinically, your titration schedule is set by your prescriber, not by what's cheapest at the next dose up.

What headline prices typically leave out

A quoted monthly figure for Mounjaro is rarely self-contained. The most common exclusions: a separate consultation fee charged each time you reorder, a prescription fee on top of the medicine cost, a delivery charge (sometimes waived only on first orders), and no included aftercare if you have questions about side effects or a missed dose.

Add those up across a six-month titration and the gap between a low headline and the actual spend widens considerably. The full breakdown of what the September increase means for private patients goes into this in more detail. The short version: comparing two headline prices without checking what each covers is a reasonable way to end up surprised mid-treatment.

Also worth flagging, some platforms offering Mounjaro at prices well below the market range after September 2025 are worth scrutinising. The MHRA has warned publicly about suspect sellers offering weight-loss medicines without a prescription and encourages anyone who encounters them to report via Yellow Card. Counterfeit tirzepatide pens have been seized in the UK; low pricing is one of the flags the MHRA highlights.

How to think about cost for a prescription medicine

The cheapest listing is the wrong thing to optimise for when the product is a prescription-only medicine dispensed by a clinician. The right questions are: is the pharmacy on the GPhC register? Does a qualified prescriber review your case, or is the process automated? Is the supply chain licensed?

At nume, we're candid that we don't compete on price. A single cost covers the consultation, a real clinician's review of your answers, the prescription, the medicine, and delivery, with aftercare included rather than billed separately. You can check everything we are and how our clinical team operates at our about page or read about our prescribing approach via our clinical lead's profile. For a medicine that requires correct titration, genuine supply, and ongoing clinical input, the price should reflect all of that. A small saving on the headline figure isn't worth a gap in any one of those. If you're a student weighing up the costs, it's also worth checking whether you qualify through our Mounjaro student discount before making a decision.

If you're ready to get a clear picture of whether Mounjaro is clinically suitable for you, speak to our prescribers via a free consultation. Orders placed before 12pm on a working day (handy if you're thinking about it around payday or ahead of a long weekend) go out the same day once approved, tracked DPD delivery the next working morning.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions